Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Deepens Its Commitment To Biologics With MorphoSys Deal Worth Up To $1 Billion

This article was originally published in The Pink Sheet Daily

Executive Summary

German mAb company’s single-partner plan includes letting deals expire with other pharmas such as Bayer Schering and J&J, as well as upping internal pipeline investments.

You may also be interested in...



Deals Of The Week Gets Better Connected, Dips A Toe In Digital Health

Digital health promises to transform the quality of health care and reduce costs, but it is not quite yet in a position to help out governments and other payers struggling to meet the demands put on their health care systems. Plus, news of deals between AstraZeneca and Roche, MorphoSys and Celgene, Aspen and Merck, and more.

Deals Of The Week Gets Better Connected, Dips A Toe In Digital Health

Digital health promises to transform the quality of health care and reduce costs, but it is not quite yet in a position to help out governments and other payers struggling to meet the demands put on their health care systems. Plus, news of deals between AstraZeneca and Roche, MorphoSys and Celgene, Aspen and Merck, and more.

MorphoSys Is At BIO Looking To Buy

Flush German biotech looks to in-license or acquire clinical stage biologics to even out its pipeline as it edges from fee-for-service to development business model.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel